Ann: PK STUDY RESULTS MOVE RP11 CLOSER TO FIRST IN HUMAN TRIALS, page-62

But that’s our role as shareholders to help fund teams/projects

I supported the cap raise at 17c - the purpose of that raise was to advance RP-11/platform to market - was expecting the ramp up of staff.

We help sow into their opportunity to do some really important/exciting science - and PYC/patients has the opportunity to reap rewards/hope if successful.

Worth remembering the probability of success is not affected by the mood of the market/share price, but the determination/ /efforts and quality of output by the team of 70.